1887

Abstract

A murine IgM monoclonal antibody (MAb H11) was developed against the type polysaccharide capsular antigen of group B streptococcus (GBS), serotype IV, after intraperitoneal immunisation of BALB/c mice with heat-killed bacteria. MAb H11 reacted in immunodiffusion with the purified polysaccharide in both its sialylated and desialylated form, giving a line of identity, and opsonised type IV GBS strains in an invitro assay. When administered at the time of intraperitoneal lethal challenge with homologous GBS, or 4 h earlier, MAb H11 protected 90% of the mice. Protection was still observed when MAb H11 was given 4 h after the challenge. This MAb was strongly effective in preventing septic arthritis induced by type IV GBS.

Loading

Article metrics loading...

/content/journal/jmm/10.1099/00222615-44-6-475
1996-06-01
2024-10-09
Loading full text...

Full text loading...

/deliver/fulltext/jmm/44/6/medmicro-44-6-475.html?itemId=/content/journal/jmm/10.1099/00222615-44-6-475&mimeType=html&fmt=ahah

References

  1. Baker C. J., Edwards M. S. Group B streptococcal infections. In Remington J. S., Klein J. O. (eds) Infectious diseases of the fetus and newborn infant Philadelphia: WB Saunders Company; 1983820–881
    [Google Scholar]
  2. Eykyn S. J., Young S. E. J., Cookson B. D. Increased community-acquired septicaemic infection with group B streptococci in adults. Lancet 1991; 338:446
    [Google Scholar]
  3. Farley M. M., Harvey R. C., Stull T. A population-based assessment of invasive disease due to group B Streptococcus in nonpregnant adults. N Engl J Med 1993; 328:1807–1811
    [Google Scholar]
  4. Rubens C. E., Wessels M. R., Heggen L. M., Kasper D. L. Transposon mutagenesis of type III group B Streptococcus: correlation of capsule expression with virulence. Proc Natl Acad Sci USA 1987; 84:7208–7212
    [Google Scholar]
  5. Baker C. J., Kasper D. L. Correlation of maternal antibody deficiency with susceptibility to neonatal group B streptococcal infection. N Engl J Med 1976; 294:753–756
    [Google Scholar]
  6. Fischer G. W., Weisman L. E., Hemming V. G. Directed immune globulin for the prevention or treatment of neonatal group B streptococcal infections: a review. Clin Immunol Immunopathol 1992; 62:S92–S97
    [Google Scholar]
  7. Fischer G. W., Weisman L. B., Hemming V. G. Intravenous immunoglobulin in neonatal group B streptococcal disease. Pharmacokinetic and safety studies in monkeys and humans. Am J Med 1984; 76:S117–S123
    [Google Scholar]
  8. Kim K. S., Wass C. A., Kang J. H., Anthony B. F. Functional activities of various preparations of human intravenous immunoglobulin against type III group B Streptococcus. J Infect Dis 1986; 153:1092–1097
    [Google Scholar]
  9. Weisman L. E., Anthony B. F., Hemming V. G., Fischer G. W. Comparison of group B streptococcal hyperimmune globulin and standard intravenously administered immune globulin in neonates. J Pediatr 1993; 122:929–937
    [Google Scholar]
  10. Egan M. L., Pritchard D. G., Dillon H. C., Gray B. M. Protection of mice from experimental infection with type III group B Streptococcus using monoclonal antibodies. J Exp Med 1983; 158:1006–1011
    [Google Scholar]
  11. Shigeoka A. O., Pincus S. H., Rote N. S., Hill H. R. Protective efficacy of hybridoma type-specific antibody against experimental infection with group-B Streptococcus. J Infect Dis 1984; 149:363–372
    [Google Scholar]
  12. Gray B. M., Egan M. L., Pritchard D. G. Specificity of monoclonal antibodies against group B Streptococcus type II and inhibition of their binding by human secretions. Pediatr Res 1988; 24:68–72
    [Google Scholar]
  13. Raff H. V., Siscoe P. J., Wolff E. A., Maloney G., Shuford W. Human monoclonal antibodies to group B Streptococcus. Reactivity and in vivo protection against multiple serotypes. J Exp Med 1988; 168:905–917
    [Google Scholar]
  14. Teti G., Calapai M., Calogero G. Specificity and protective activity of murine monoclonal antibodies directed against the capsular polysaccharide of type III group B streptococci. Hybridoma 1992; 11:13–22
    [Google Scholar]
  15. Hill H. R., Kelsey D. K., Gonzales L. A., Raff H. V. Monoclonal antibodies in the therapy of experimental neonatal group B streptococcal disease. Clin Immunol Immunopathol 1992; 62:S87–S91
    [Google Scholar]
  16. Tissi L., Marconi P., Mosci P. Experimental model of type IV Streptococcus agalactiae (Group B Streptococcus) infection in mice with early development of septic arthritis. Infect Immun 1990; 58:3093–3100
    [Google Scholar]
  17. Rabinowitz S., Feme M., Halfon S. T. Group B streptococci: different serotypes associated with clinical infection. Lab Pract 1980; 29:733–734
    [Google Scholar]
  18. Jelinkova J., Motlova J. Worldwide distribution of two new serotypes of group B streptococci: type IV and provisional type V. J Clin Microbiol 1985; 21:361–362
    [Google Scholar]
  19. Wessels M. R., Benedi V. J., Jennings H. J., Michon F., DiFabio J. L., Kasper D. L. Isolation and characterization of type IV group B Streptococcus capsular polysaccharide. Infect Immun 1989; 57:1089–1094
    [Google Scholar]
  20. Molinari A., von Hunolstein C., Donelli G., Paradisi S., Aranda G., Orefici G. Effects of some capsular components on pathogenicity of type IV and provisional type V group B streptococci. FEMS Microbiol Lett 1987; 41:69–72
    [Google Scholar]
  21. von Hunolstein C., D’ascenzi S., Wagner B. Immuno-chemistry of capsular type polysaccharide and virulence properties of type VI Streptococcus agalactiae (Group B streptococci). Infect Immun 1993; 61:1272–1280
    [Google Scholar]
  22. Lancefield R. C. A serological differentiation of specific types of bovine hemolytic streptococci (group B). J Exp Med 1934; 59:441–458
    [Google Scholar]
  23. Malavasi F., Caligaris-Cappio F., Milanese C., Dellabona P., Richiardi P., Carbonara A. O. Characterization of a murine monoclonal antibody specific for human early lymphohema-poietic cells. Human Immunol 1984; 9:9–20
    [Google Scholar]
  24. Ouchterlony O. Diffusion-in-gel methods for immunological analysis. Prog Allergy 1958; 5:1–78
    [Google Scholar]
  25. Reed L., Muench H. A simple method of estimating fifty per cent endpoints. Am J Hyg 1938; 27:493–397
    [Google Scholar]
  26. Lancefield R. C., McCarty M., Everly W. N. Multiple mouse-protective antibodies directed against group B streptococci. J Exp Med 1975; 142:165–179
    [Google Scholar]
  27. Shigeoka A. O., Hall R. T., Hill H. R. Blood-transfusion in group-B streptococcal sepsis. Lancet 1978; 1:636–638
    [Google Scholar]
  28. Butkus Small C., Slater L. N., Lowry F. D., Small R. D., Salvati E. A., Casey J. L. Group B streptococcal arthritis in adults. Am J Med 1984; 76:367–375
    [Google Scholar]
  29. Raff H. Y., Bradley C., Brady W. Comparison of functional activities between IgGl and IgM class-switched human monoclonal antibodies reactive with group B streptococci or Escherichia coli Kl. J Infect Dis 1991; 163:346–354
    [Google Scholar]
/content/journal/jmm/10.1099/00222615-44-6-475
Loading
/content/journal/jmm/10.1099/00222615-44-6-475
Loading

Data & Media loading...

This is a required field
Please enter a valid email address
Approval was a Success
Invalid data
An Error Occurred
Approval was partially successful, following selected items could not be processed due to error